Elanco Animal Health Incorporated (ELAN)
NYSE: ELAN · Real-Time Price · USD
23.13
+0.62 (2.75%)
May 5, 2026, 1:56 PM EDT - Market open
Elanco Animal Health Stock Forecast
Stock Price Forecast
The 9 analysts that cover Elanco Animal Health stock have a consensus rating of "Strong Buy" and an average price target of $27.89, which forecasts a 20.58% increase in the stock price over the next year. The lowest target is $23 and the highest is $30.
Price Target: $27.89 (+20.58%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Elanco Animal Health stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 3 |
| Buy | 5 | 6 | 7 | 7 | 7 | 6 |
| Hold | 2 | 2 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 10 | 10 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy Initiates $30 | Strong Buy | Initiates | $30 | +29.70% | Apr 15, 2026 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $22 → $24 | Hold | Maintains | $22 → $24 | +3.76% | Feb 25, 2026 |
| Keybanc | Keybanc | Buy Maintains $27 → $29 | Buy | Maintains | $27 → $29 | +25.38% | Feb 25, 2026 |
| Leerink Partners | Leerink Partners | Buy Maintains $26 → $30 | Buy | Maintains | $26 → $30 | +29.70% | Feb 24, 2026 |
| JP Morgan | JP Morgan | Buy Maintains $24 → $28 | Buy | Maintains | $24 → $28 | +21.05% | Feb 19, 2026 |
Financial Forecast
Revenue This Year
5.10B
from 4.72B
Increased by 8.21%
Revenue Next Year
5.37B
from 5.10B
Increased by 5.31%
EPS This Year
1.05
from -0.47
EPS Next Year
1.19
from 1.05
Increased by 13.49%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 5.3B | 5.6B | ||||||
| Avg | 5.1B | 5.4B | ||||||
| Low | 4.9B | 5.1B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 11.7% | 9.5% | ||||||
| Avg | 8.2% | 5.3% | ||||||
| Low | 3.5% | -0.5% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 1.11 | 1.30 | ||||||
| Avg | 1.05 | 1.19 | ||||||
| Low | 0.98 | 1.11 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | 23.7% | ||||||
| Avg | - | 13.5% | ||||||
| Low | - | 5.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.